Scailyte leverages the power of single-cell technologies and its proprietary data analysis platform ScaiVision. This union enables single-cell level precision in R&D and development of novel targeted assays in manufacturing of cell therapies. While cutting production and treatment costs of up to 50%, Scailyte’s solutions for patient stratification, optimised R&D and QA processes will make cell therapy accessible to more patients with maximum treatment efficacy.
Continue readingScaiVision AI platform: project workflow to facilitate drug development
ScaiVision unravels hidden secrets of complex single-cell multiomics data to extract composite biomarkers associated with different cell populations. Using a convolutional neural network and representation learning, ScaiVision automatically learns molecular patterns associated with relevant clinical outcomes. These signatures can then be applied to classify new samples and develop diagnostic assay prototypes.
Continue readingGenerating clinically relevant insights from single-cell data
ScaiVision performs as the best-in-class algorithm at identifying molecular biomarkers, which accurately predict clinical status of the samples. Analysis with ScaiVision unlocks an unparalleled level of high-resolution and clinically relevant discoveries in single-cell datasets.
Continue reading